New York, USA - May 27, 2026 - The enhanced suite is designed to help microbiome therapeutic developers investigate how live microbial candidates interact with host metabolic, neural, and immune pathways, bridging the gap between strain identification and translational preclinical evidence.
Addressing the Complexity of Microbiome-Host Interactions
The therapeutic potential of LBPs extends beyond simple gut health, influencing systemic metabolic, neurological, and immune functions. Recognizing this complexity, Creative Biolabs has developed specialized assay systems to quantify these interactions with high precision.
"The next generation of biotherapeutics relies on our ability to decode the chemical language between symbiotic bacteria and host receptors," said a chief scientist at Creative Biolabs. "Our latest platforms don't just observe effects; they map the specific pathways—whether through hormonal triggers like GLP-1 or neural pathways like the vagus nerve—that define a candidate's clinical efficacy."
Key Technical Pillars of the Enhanced Suite
The expanded services focus on three critical therapeutic areas:
Metabolic Regulation: Utilizing sophisticated enteroendocrine L-cell models, researchers can now perform high-throughput screening of LBPs that stimulate GLP-1 secretion, offering new avenues for treating type 2 diabetes and obesity.
The Gut-Brain Axis: To address neurodegenerative and psychiatric disorders, the company has refined its vagus nerve activation assays. These models track gut-brain signaling to evaluate how microbial metabolites influence central nervous system (CNS) health.
Immuno-Oncology Synergies: In the fight against cancer, Creative Biolabs provides murine tumor models to evaluate how LBPs can enhance the efficacy of PD-1/PD-L1 inhibitors, overcoming resistance through microbiota modulation.
Technical Analysis: Bridging the Preclinical Gap
To assist researchers in navigating the complexities of microbiome therapeutic development, Creative Biolabs has organized its platform around key translational questions:
Q: How does the platform ensure the physiological relevance of L-cell assays? A: Our models utilize primary cell cultures and organoids that replicate the polarized structure of the intestinal epithelium, ensuring that GLP-1 secretion data correlates closely with in vivo metabolic responses.
Q: What parameters are measured in gut-brain signaling studies? A: We focus on electrophysiological recordings of the vagus nerve and the quantification of neuroactive metabolites (e.g., GABA, serotonin) using LC-MS/MS, providing a granular view of the signaling cascade.
Industry Recognition and Trust
Creative Biolabs' commitment to quality is reflected in its technical rigor and client feedback. A senior researcher from a leading biotechnology firm noted in a recent review: "The specificity of the LBP-PD-1 synergy models provided by Creative Biolabs allowed us to identify a lead candidate six months ahead of schedule, thanks to their robust murine tumor data."
About Creative Biolabs
Creative Biolabs is a premier provider of microbial services, specializing in the discovery and development of live biotherapeutic products. With a multidisciplinary team of microbiologists and pharmacologists, the company supports global pharmaceutical partners in navigating the complexities of the human microbiome.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email:
Send EmailPhone: 1-631-830-6441
Country: United States
Website:
https://live-biotherapeutic.creative-biolabs.com